AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28315160 — intervention group
Group type: COMPARATOR
Intervention: MCLR intraperitoneal injection (150 μg kg-1 BW)
Number of subjects: 5
Study 26289437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tastants (quinine, rebaudioside A, monosodium glutamate)
Number of subjects: 15
Study 26289437 — intervention group
Group type: EXPERIMENTAL
Intervention: Umami tastant
Number of subjects: 15
Study 26289437 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tap water)
Number of subjects: 15
Study 24139765 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus commitment contract, team incentives, and text message reminders for smoking cessation at 3 months
Number of subjects: 201
Study 24139765 — intervention group
Group type: COMPARATOR
Intervention: Counseling (control group)
Number of subjects: 201
Study 24139765 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus commitment contract, team incentives, and text message reminders for smoking cessation at 6 months
Number of subjects: 201
Study 24139765 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus commitment contract, team incentives, and text message reminders for smoking cessation at 14 months
Number of subjects: 201
Study 24139765 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 201
Study 21256876 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine (2 doses)
Number of subjects: 375
Study 21256876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 dose)
Number of subjects: 375
Study 19690450 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing with clear water twice weekly (Group B)
Number of subjects: 57
Study 19690450 — intervention group
Group type: COMPARATOR
Intervention: Washing with a washcloth moistened with clear water twice weekly (Group W)
Number of subjects: 57
Study 17035091 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered plasma
Number of subjects: 24
Study 17035091 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood and RBC
Number of subjects: 24
Study 17035091 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma and RBC
Number of subjects: 24
Study 17035091 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered plasma
Number of subjects: 24
Study 12819161 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 2000
Study 12819161 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 2000
Study 12819161 — intervention group
Group type: EXPERIMENTAL
Intervention: Term SGA infants
Number of subjects: 2000
Study 12819161 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight at 6 weeks of age
Number of subjects: 2000
Study 12819161 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking
Number of subjects: 2000
Study 12819161 — intervention group
Group type: EXPERIMENTAL
Intervention: General weaning practices
Number of subjects: 2000
Study 11097666 — intervention group
Group type: EXPERIMENTAL
Intervention: Air group (2 mL of air)
Number of subjects: 160
Study 11097666 — intervention group
Group type: COMPARATOR
Intervention: Saline group (2 mL of 0.9% saline)
Number of subjects: 160
Study 9357887 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil at 0 ng/ml
Number of subjects: 6
Study 9357887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at 25 ng/ml
Number of subjects: 6
Study 9357887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at 50 ng/ml
Number of subjects: 6
Study 9357887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at 100 ng/ml
Number of subjects: 6
Study 9357887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil administration
Number of subjects: 6
Study 8211353 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive therapy for myocardial ischemia and infarction in elderly patients
Number of subjects: 0
Study 3609435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ham's F10 supplemented with cord serum
Number of subjects: 321
Study 3609435 — intervention group
Group type: COMPARATOR
Intervention: Menezo B2 used without serum
Number of subjects: 321
Study 28956535 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants with platelet rich fibrin (PRF)
Number of subjects: 17
Study 28956535 — intervention group
Group type: COMPARATOR
Intervention: Immediate implants without PRF (control)
Number of subjects: 17
Study 28956535 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants with PRF
Number of subjects: 17
Study 29084304 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-based denture liners
Number of subjects: 30
Study 29084304 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic resin-based denture liners
Number of subjects: 30
Study 29084304 — intervention group
Group type: COMPARATOR
Intervention: Control (acrylic resin)
Number of subjects: 30
Study 25346382 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic growth (PTG)
Number of subjects: 564
Study 25346382 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, life-altering stressful life event (SLE)
Number of subjects: 564
Study 23116485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg)
Number of subjects: 0
Study 23116485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg) with FF/VI (200/25 μg)
Number of subjects: 0
Study 23116485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20613477 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 61
Study 20613477 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 61
Study 20613477 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 61
Study 20613477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 61
Study 20613477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 18847427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) in the induction phase
Number of subjects: 268
Study 18847427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and MPA in the induction phase (14 days)
Number of subjects: 268
Study 18847427 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 268
Study 18847427 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchanges
Number of subjects: 268
Study 18847427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose corticoids
Number of subjects: 268
Study 18847427 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and melphalan
Number of subjects: 268
Study 18847427 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosidate
Number of subjects: 268
Study 18847427 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF-alpha agents
Number of subjects: 268
Study 20204652 — intervention group
Group type: COMPARATOR
Intervention: 40,000 IU of vitamin D per week for 1 year
Number of subjects: 10229
Study 20204652 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10229
Study 15832833 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction counselling
Number of subjects: 35
Study 12018902 — intervention group
Group type: EXPERIMENTAL
Intervention: K-ras mutations in colorectal cancer samples from Israel
Number of subjects: 105
Study 12018902 — intervention group
Group type: COMPARATOR
Intervention: Comparison of K-ras mutations in colorectal cancer in Israel with other countries
Number of subjects: 105
Study 9669829 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY-046
Number of subjects: 16
Study 9669829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8067563 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 56
Study 8067563 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 56
Study 2968263 — intervention group
Group type: EXPERIMENTAL
Intervention: doxifluridine 4000 mg/m2
Number of subjects: 52
Study 2968263 — intervention group
Group type: COMPARATOR
Intervention: fluorouracil 450 mg/m2 i.v.
Number of subjects: 52
Study 31216000 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and child 5‐year serum PFAS concentrations
Number of subjects: 80
Study 31216000 — intervention group
Group type: COMPARATOR
Intervention: PFASs measured at ages 7 to 13 years
Number of subjects: 80
Study 28364493 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (N = 26)
Number of subjects: 84
Study 28364493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (N = 30)
Number of subjects: 84
Study 28364493 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 28)
Number of subjects: 84
Study 26567275 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-only supervised exercise training (SET) for 12 weeks
Number of subjects: 35
Study 26567275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of treadmill and lower-limb resistance supervised exercise training (SET) for 12 weeks
Number of subjects: 35
Study 25123230 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based self-help problem solving treatment (PST) for affective symptoms
Number of subjects: 286
Study 25123230 — intervention group
Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 286
Study 22365697 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with 20 mg/kg body weight oxytetracycline intramuscular, 4% lotagen intrauterine, and 500 μg cloprostenol intramuscular.
Number of subjects: 60
Study 22365697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 60
Study 22365697 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with 20 mg/kg body weight oxytetracycline intramuscular, 4% lotagen intrauterine, and 500 μg cloprostenol intramuscular, based on bursal size.
Number of subjects: 60
Study 19732200 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 21
Study 19732200 — intervention group
Group type: COMPARATOR
Intervention: Standard dose chemotherapy (SC)
Number of subjects: 21
Study 19732200 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio
Number of subjects: 21
Study 17101267 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanding collagen tablets
Number of subjects: 12
Study 17101267 — intervention group
Group type: COMPARATOR
Intervention: Small sustained release hydrocolloid tablets
Number of subjects: 12
Study 15010336 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐h continuous infusion of [1,2‐(13)C(2)]taurine (3.1 +/- 0.2 micromol x kg(‐1) x h(‐1))
Number of subjects: 5
Study 15010336 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of [(13)C(2)]taurine (3.0 +/- 0.1 micromol/kg)
Number of subjects: 5
Study 15010336 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of tracer
Number of subjects: 5
Study 11604383 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completion diary
Number of subjects: 0
Study 11604383 — intervention group
Group type: COMPARATOR
Intervention: MYMOP2
Number of subjects: 0
Study 9610692 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (370 mg/m2) plus folinic acid (200 mg/m2) administered daily for 5 days every 4 weeks for 6 cycles
Number of subjects: 888
Study 9610692 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 888
Study 7601177 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen LATTM (40 mg) applied via a nonwoven polyester patch every 12 hours for 14 days
Number of subjects: 80
Study 7601177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (patch without active ingredient)
Number of subjects: 80
Study 3072179 — intervention group
Group type: EXPERIMENTAL
Intervention: autogenic training
Number of subjects: 117
Study 3072179 — intervention group
Group type: EXPERIMENTAL
Intervention: biofeedback
Number of subjects: 117
Study 3072179 — intervention group
Group type: EXPERIMENTAL
Intervention: breathing‐relaxation training
Number of subjects: 117
Study 3072179 — intervention group
Group type: COMPARATOR
Intervention: psychological placebo
Number of subjects: 117
Study 29401546 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine and iodide therapy
Number of subjects: 0
Study 29401546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27496717 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable screws
Number of subjects: 40
Study 27496717 — intervention group
Group type: COMPARATOR
Intervention: Steel screws
Number of subjects: 40
Study 24029743 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD participants undergoing baseline visit and three annual follow-up examinations with quarterly telephone calls.
Number of subjects: 3200
Study 24029743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudication of exacerbations and mortality.
Number of subjects: 3200
Study 23795985 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ranibizumab (0.5 mg, 0.05 cc)
Number of subjects: 48
Study 23795985 — intervention group
Group type: COMPARATOR
Intervention: IV bevacizumab (1.5 mg, 0.06 cc)
Number of subjects: 48
Study 23795985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 23795985 — intervention group
Group type: COMPARATOR
Intervention: IV bevacizumab
Number of subjects: 48
Study 23795985 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ranibizumab
Number of subjects: 48
Study 19752567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lavage with hypertonic saline solution 3 times daily
Number of subjects: 45
Study 19752567 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local therapy)
Number of subjects: 45
Study 18664346 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Sanju Formula (YQSJF)
Number of subjects: 67
Study 18664346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 16466005 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal oblique aponeurosis flap (IOAF) repair
Number of subjects: 0
Study 16466005 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein's tension-free repair
Number of subjects: 0
Study 12030615 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg dexamethasone
Number of subjects: 6
Study 12030615 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone
Number of subjects: 6
Study 12030615 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg dexamethasone
Number of subjects: 6
Study 12030615 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone administration at 21:00 h vs 23:00 h
Number of subjects: 6
Study 10193725 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty
Number of subjects: 506
Study 7605283 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia
Number of subjects: 116
Study 7605283 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia
Number of subjects: 116
Study 2225504 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 50
Study 2225504 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 50
Study 367255 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (Resibion) 500 mg
Number of subjects: 16
Study 367255 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (Resibion) 250 mg every 6 hours
Number of subjects: 16
Study 367255 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated erythromycin base (Etromycin) 250 mg every 6 hours
Number of subjects: 16
Study 31947628 — intervention group
Group type: EXPERIMENTAL
Intervention: Policaptil Gel Retard (PGR)
Number of subjects: 46
Study 31947628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 29359880 — intervention group
Group type: EXPERIMENTAL
Intervention: High insertion torque (≥50 Ncm)
Number of subjects: 116
Study 29359880 — intervention group
Group type: COMPARATOR
Intervention: Regular insertion torque (<50 Ncm)
Number of subjects: 116
Study 27467038 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-μm cap thickness
Number of subjects: 40
Study 27467038 — intervention group
Group type: COMPARATOR
Intervention: 140-μm cap thickness
Number of subjects: 40
Study 24733648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy added to standard treatment (deep breathing exercises, mobilizations, incentive spirometry)
Number of subjects: 104
Study 24733648 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (medical treatment and drainage)
Number of subjects: 104
Study 23326136 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 60
Study 23326136 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 60
Study 20819541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose gel
Number of subjects: 560
Study 20819541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 560
Study 20819541 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 560
Study 18295798 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 59
Study 18295798 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 59
Study 18295798 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (in African American and Hispanic subjects)
Number of subjects: 59
Study 16466166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Capsule (FHC)
Number of subjects: 50
Study 16466166 — intervention group
Group type: COMPARATOR
Intervention: Control group (ineffective group)
Number of subjects: 50
Study 14625122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal Replacement Therapy (HRT)
Number of subjects: 20
Study 10993129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 308
Study 10993129 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 308
Study 9055715 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for eight weeks plus amoxycillin 750 mg twice daily for weeks 7 and 8
Number of subjects: 107
Study 9055715 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg once daily for eight weeks
Number of subjects: 107
Study 8396084 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for three days
Number of subjects: 62
Study 8396084 — intervention group
Group type: COMPARATOR
Intervention: Dicloxacillin 250 mg four times a day for seven days
Number of subjects: 62
Study 3729711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin sodium and metronidazole
Number of subjects: 65
Study 3729711 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G sodium, streptomycin, and metronidazole
Number of subjects: 65
Study 29407540 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus exercise (S+EX)
Number of subjects: 121
Study 29407540 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (S)
Number of subjects: 121
Study 26725707 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 000 IU of vitamin D3 every 3 months
Number of subjects: 60
Study 26725707 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 000 IU of vitamin D3 every 3 months
Number of subjects: 60
Study 26725707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26725707 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 000 IU of vitamin D3
Number of subjects: 60
Study 26725707 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 000 IU of vitamin D3
Number of subjects: 60
Study 25204412 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoablation group (CT-guided percutaneous chemical ablation)
Number of subjects: 31
Study 25204412 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation group (additional radiotherapy, second-line chemotherapy, or both)
Number of subjects: 31
Study 22288725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose azithromycin (250 mg orally daily for 5 days then 2× weekly for a total of 12 weeks)
Number of subjects: 11
Study 22288725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose azithromycin
Number of subjects: 11
Study 20394966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 80
Study 20394966 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 80
Study 18551087 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise and hormone therapy (estradiol valerate 1 mg/d orally)
Number of subjects: 44
Study 18551087 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise and placebo
Number of subjects: 44
Study 18551087 — intervention group
Group type: COMPARATOR
Intervention: Sedentary and hormone therapy (estradiol valerate 1 mg/d orally)
Number of subjects: 44
Study 18551087 — intervention group
Group type: COMPARATOR
Intervention: Sedentary and placebo
Number of subjects: 44
Study 16083524 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 100 mg/kg into the cardiopulmonary bypass prime followed by infusion at 20 mg/kg/h
Number of subjects: 40
Study 16083524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11825530 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior interbody fusion with cage (cage group)
Number of subjects: 32
Study 11825530 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion with RF fixation (RF group)
Number of subjects: 32
Study 9744431 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT only pacing
Number of subjects: 10
Study 9744431 — intervention group
Group type: EXPERIMENTAL
Intervention: QT pacing
Number of subjects: 10
Study 9744431 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT = QT pacing
Number of subjects: 10
Study 9744431 — intervention group
Group type: EXPERIMENTAL
Intervention: QT and ACT = QT pacing
Number of subjects: 10
Study 7913854 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol (PR)
Number of subjects: 20
Study 7913854 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 20
Study 7913854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials (C and PR)
Number of subjects: 20
Study 7913854 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (UB and LB)
Number of subjects: 20